首页 > 过刊浏览>2023年第卷第9期 >1114-1120. DOI:10.12138/j.issn.1671-9638.20234314
PDF HTML阅读 XML下载 导出引用 引用提醒
新型冠状病毒感染后综合征的研究进展
作者:
作者单位:

1.青岛大学附属青岛市海慈医院(青岛市中医医院) 康复科, 山东 青岛 266000;2.青岛中西医结合医院护理部, 山东 青岛 266000;3.青岛大学附属青岛市海慈医院(青岛市中医医院)肺病科, 山东 青岛 266000;4.青岛阜外心血管病医院急诊科, 山东 青岛 266000

通讯作者:

王增涛  E-mail: malcomzhang111@163.com

中图分类号:

R183


Research progress in post-COVID -19 syndrome
Author:
Affiliation:

1.Department of Rehabilitation, Qingdao Hiser Hospital Affiliated toQingdao University [Qingdao Traditional Chinese Medi-cine Hospital], Qingdao 266000, China;2.Nursing Department, Qingdao Integrated Traditional Chinese and Western Medicine Hospital, Qingdao 266000, China;3.Department of Pulmonary Diseases, Qingdao Hiser Hospital Affiliated to Qingdao University [Qingdao Traditional Chinese Medicine Hospital], Qingdao 266000, China;4.Department of Emergency, Qingdao Fuwai Cardiovascular Disease Hospital, Qingdao 266000, China

  • 摘要
    • |
  • 访问统计
    • |
  • 参考文献 [60]
    • |
  • 相似文献 [20]
    • |
  • 文章评论
    摘要:

    新型冠状病毒(简称新冠病毒)感染后综合征(Post-COVID -19 syndrome)又称为长新冠病毒感染(Long COVID)和新冠病毒感染后状态(Post-COVID -19 condition), 是发生于新冠病毒感染急性期后的一系列症状, 以疲劳、头痛、认知障碍、肌肉骨骼疼痛、胸闷气短、抑郁失眠为主要表现, 严重影响患者的生活质量和工作能力。新冠病毒感染后综合征已引起国外医学界的重视并对其发病机制和诊疗方案进行了一系列研究。由于中国在全球疫情开始的前三年采取积极有效的疫情防控措施, 国内新冠病毒感染的病例相对较少。随着2023年初国家疫情防控政策的调整, 短时期内出现了全国范围内的大规模感染。目前, 国内新冠病毒感染急性期的救治工作已基本结束, 新冠病毒感染后综合征的诊疗将是未来各级医院工作的重点。本文对新冠病毒感染后综合征的国外研究进展进行综述, 以期为国内新冠病毒感染后综合征的诊疗工作提供参考依据。

    Abstract:

    Post-COVID -19 syndrome, also known as long COVID and post-COVID -19 condition, is a series of symptoms occurring after the acute phase of COVID -19 infection. The main symptoms are fatigue, headache, cognitive impairment, musculoskeletal pain, dyspnea, depression, and insomnia. Patients' quality of life and work ability can be seriously affected. Post-COVID -19 syndrome has gained the attention in the international medical community, leading to a series of studies on its pathogenesis, diagnosis and treatment options. Due to the effective epidemic prevention and control measures taken in China in the first three years of the global epidemic, the number of COVID -19 cases in China has been relatively low. With the adjustment of national epidemic prevention and control policies in early 2023, China has experienced large-scale infections nationwide in a short period. Currently, the treatment of acute COVID -19 in China has mostly concluded, and the diagnosis and treatment of post-COVID -19 syndrome will be the focus of hospitals at all levels in the future. This article summarizes the international research progress in post-COVID -19 syndrome, aiming to provide reference for the diagnosis and treatment of post-COVID -19 syndrome in China.

    参考文献
    [1] Higgins V, Sohaei D, Diamandis EP, et al. COVID -19: from an acute to chronic disease? Potential long-term health consequences[J]. Crit Rev Clin Lab Sci, 2021, 58(5): 297-310.
    [2] Lechner-Scott J, Levy M, Hawkes C, et al. Long COVID or post COVID -19 syndrome[J]. Mult Scler Relat Disord, 2021, 55: 103268.
    [3] Venkatesan P. NICE guideline on long COVID[J]. Lancet Respir Med, 2021, 9(2): 129.
    [4] Soriano JB, Murthy S, Marshall JC, et al. A clinical case definition of post-COVID -19 condition by a Delphi consensus[J]. Lancet Infect Dis, 2022, 22(4): e102-e107.
    [5] Global Burden of Disease Long COVID Collaborators, Wulf Hanson S, Abbafati C, et al. Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID -19 in 2020 and 2021[J]. JAMA, 2022, 328(16): 1604-1615.
    [6] Taquet M, Dercon Q, Luciano S, et al. Incidence, co-occurrence, and evolution of long-COVID features: a 6-month re-trospective cohort study of 273, 618 survivors of COVID -19[J]. PLoS Med, 2021, 18(9): e1003773.
    [7] Chan AT, Drew DA, Nguyen LH, et al. The coronavirus pandemic epidemiology (COPE) consortium: a call to action[J]. Cancer Epidemiol Biomarkers Prev, 2020, 29(7): 1283-1289.
    [8] Taquet M, Dercon Q, Harrison PJ. Six-month sequelae of post-vaccination SARS-CoV-2 infection: a retrospective cohort study of 10, 024 breakthrough infections[J]. Brain Behav Immun, 2022, 103: 154-162.
    [9] Ren AL, Digby RJ, Needham EJ. Neurological update: COVID -19[J]. J Neurol, 2021, 268(11): 4379-4387.
    [10] Baig AM. Deleterious outcomes in long-hauler COVID -19: the effects of SARS-CoV-2 on the CNS in chronic COVID syndrome[J]. ACS Chem Neurosci, 2020, 11(24): 4017-4020.
    [11] Gasmi A, Tippairote T, Mujawdiya PK, et al. Neurological involvements of SARS-CoV2 infection[J]. Mol Neurobiol, 2021, 58(3): 944-949.
    [12] Lu YP, Li XX, Geng DY, et al. Cerebral micro-structural changes in COVID -19 patients-an MRI-based 3-month follow-up study[J]. EClinicalMedicine, 2020, 25: 100484.
    [13] Qin YY, Wu JF, Chen T, et al. Long-term microstructure and cerebral blood flow changes in patients recovered from COVID -19 without neurological manifestations[J]. J Clin Invest, 2021, 131(8): e147329.
    [14] Guedj E, Campion JY, Dudouet P, et al. 18F-FDG brain PET hypometabolism in patients with long COVID[J]. Eur J Nucl Med Mol Imaging, 2021, 48(9): 2823-2833.
    [15] Wood E, Hall KH, Tate W. Role of mitochondria, oxidative stress and the response to antioxidants in myalgic encephalomyelitis/chronic fatigue syndrome: a possible approach to SARS-CoV-2' long-haulers'?[J]. Chronic Dis Transl Med, 2021, 7(1): 14-26.
    [16] Lee MH, Perl DP, Nair G, et al. Microvascular injury in the brains of patients with COVID -19[J]. N Engl J Med, 2021, 384(5): 481-483.
    [17] Attal N, Martinez V, Bouhassira D. Potential for increased prevalence of neuropathic pain after the COVID -19 pandemic[J]. Pain Rep, 2021, 6(1): e884.
    [18] de Melo GD, Lazarini F, Levallois S, et al. COVID -19-related anosmia is associated with viral persistence and inflammation in human olfactory epithelium and brain infection in hamsters[J]. Sci Transl Med, 2021, 13(596): eabf8396.
    [19] Doyle ME, Appleton A, Liu QR, et al. Human type Ⅱ taste cells express angiotensin-converting enzyme 2 and are infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)[J]. Am J Pathol, 2021, 191(9): 1511-1519.
    [20] ?stergaard L. SARS CoV-2 related microvascular damage and symptoms during and after COVID -19: consequences of capillary transit-time changes, tissue hypoxia and inflammation[J]. Physiol Rep, 2021, 9(3): e14726.
    [21] Evans PC, Rainger GE, Mason JC, et al. Endothelial dysfunction in COVID -19: a position paper of the ESC working group for atherosclerosis and vascular biology, and the ESC council of basic cardiovascular science[J]. Cardiovasc Res, 2020, 116(14): 2177-2184.
    [22] Roberts KA, Colley L, Agbaedeng TA, et al. Vascular manifestations of COVID -19-thromboembolism and microvascular dysfunction[J]. Front Cardiovasc Med, 2020, 7: 598400.
    [23] Wallukat G, Hohberger B, Wenzel K, et al. Functional autoantibodies against G-protein coupled receptors in patients with persistent long-COVID -19 symptoms[J]. J Transl Autoimmun, 2021, 4: 100100.
    [24] Rali AS, Ranka S, Shah Z, et al. Mechanisms of myocardial injury in coronavirus disease 2019[J]. Card Fail Rev, 2020, 6: e15.
    [25] Blitshteyn S, Whitelaw S. Postural orthostatic tachycardia syndrome (POTS) and other autonomic disorders after COVID -19 infection: a case series of 20 patients[J]. Immunol Res, 2021, 69(2): 205-211.
    [26] Goldstein DS. The possible association between COVID -19 and postural tachycardia syndrome[J]. Heart Rhythm, 2021, 18(4): 508-509.
    [27] Ojo AS, Balogun SA, Williams OT, et al. Pulmonary fibrosis in COVID -19 survivors: predictive factors and risk reduction strategies[J]. Pulm Med, 2020, 2020: 6175964.
    [28] P KM, Sivashanmugam K, Kandasamy M, et al. Repurposing of histone deacetylase inhibitors: a promising strategy to combat pulmonary fibrosis promoted by TGF-β signalling in COVID -19 survivors[J]. Life Sci, 2021, 266: 118883.
    [29] Tanni SE, Fabro AT, de Albuquerque A, et al. Pulmonary fibrosis secondary to COVID -19: a narrative review[J]. Expert Rev Respir Med, 2021, 15(6): 791-803.
    [30] Dhawan RT, Gopalan D, Howard L, et al. Beyond the clot: perfusion imaging of the pulmonary vasculature after COVID -19[J]. Lancet Respir Med, 2021, 9(1): 107-116.
    [31] Carsana L, Sonzogni A, Nasr A, et al. Pulmonary post-mortem findings in a series of COVID -19 cases from northern Italy: a two-centre descriptive study[J]. Lancet Infect Dis, 2020, 20(10): 1135-1140.
    [32] De Michele S, Sun Y, Yilmaz MM, et al. Forty postmortem examinations in COVID -19 patients[J]. Am J Clin Pathol, 2020, 154(6): 748-760.
    [33] Schaller T, Hirschbühl K, Burkhardt K, et al. Postmortem examination of patients with COVID -19[J]. JAMA, 2020, 323(24): 2518-2520.
    [34] Dani M, Dirksen A, Taraborrelli P, et al. Autonomic dysfunction in 'long COVID': rationale, physiology and management strategies[J]. Clin Med (Lond), 2021, 21(1): e63-e67.
    [35] Taverne J, Salvator H, Leboulch C, et al. High incidence of hyperventilation syndrome after COVID -19[J]. J Thorac Dis, 2021, 13(6): 3918-3922.
    [36] Howell JB. The hyperventilation syndrome: a syndrome under threat?[J]. Thorax, 1997, 52(Suppl 3): S30-S34.
    [37] Schultheiβ C, Willscher E, Paschold L, et al. The IL-1β, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID -19[J]. Cell Rep Med, 2022, 3(6): 100663.
    [38] Jacobs JJL. Persistent SARS-2 infections contribute to long COVID -19[J]. Med Hypotheses, 2021, 149: 110538.
    [39] Afrin LB, Weinstock LB, Molderings GJ. COVID -19 hyperinflammation and post-COVID -19 illness may be rooted in mast cell activation syndrome[J]. Int J Infect Dis, 2020, 100: 327-332.
    [40] Kazama I. Stabilizing mast cells by commonly used drugs: a novel therapeutic target to relieve post-COVID syndrome?[J]. Drug Discov Ther, 2020, 14(5): 259-261.
    [41] Yong SJ. Long COVID or post-COVID -19 syndrome: putative pathophysiology, risk factors, and treatments[J]. Infect Dis (Lond), 2021, 53(10): 737-754.
    [42] Galeotti C, Bayry J. Autoimmune and inflammatory diseases following COVID -19[J]. Nat Rev Rheumatol, 2020, 16(8): 413-414.
    [43] Gaebler C, Wang ZJ, Lorenzi JCC, et al. Evolution of antibody immunity to SARS-CoV-2[J]. Nature, 2021, 591(7851): 639-644.
    [44] Dennis A, Wamil M, Alberts J, et al. Multiorgan impairment in low-risk individuals with post-COVID -19 syndrome: a prospective, community-based study[J]. BMJ Open, 2021, 11(3): e048391.
    [45] Bai Y, Xu JL, Chen LJ, et al. Inflammatory response in lungs and extrapulmonary sites detected by [18F] fluorodeoxyglucose PET/CT in convalescing COVID -19 patients tested negative for coronavirus[J]. Eur J Nucl Med Mol Imaging, 2021, 48(8): 2531-2542.
    [46] Raman B, Cassar MP, Tunnicliffe EM, et al. Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exer- cise capacity, cognition, quality of life and mental health, post-hospital discharge[J]. EClinicalMedicine, 2021, 31: 100683.
    [47] Le Stang MB, Desenclos J, Flamant M, et al. The good treatment, the bad virus, and the ugly inflammation: pathophysio-logy of kidney involvement during COVID -19[J]. Front Phy-siol, 2021, 12: 613019.
    [48] Gentile S, Strollo F, Mambro A, et al. COVID -19, ketoacidosis and new-onset diabetes: are there possible cause and effect relationships among them?[J]. Diabetes Obes Metab, 2020, 22(12): 2507-2508.
    [49] Silva Andrade B, Siqueira S, de Assis Soares WR, et al. Long-COVID and post-COVID health complications: an up-to-date review on clinical conditions and their possible molecular mechanisms[J]. Viruses, 2021, 13(4): 700.
    [50] Raman B, Bluemke DA, Lüscher TF, et al. Long COVID: post-acute sequelae of COVID -19 with a cardiovascular focus[J]. Eur Heart J, 2022, 43(11): 1157-1172.
    [51] 顾宫, 康昊男, 车超群, 等. 武汉雷神山医院部分病区320例COVID -19患者康复期随访研究[J]. 中国感染控制杂志, 2022, 21(8): 729-741.
    [52] Poenaru S, Abdallah SJ, Corrales-Medina V, et al. COVID -19 and post-infectious myalgic encephalomyelitis/chronic fatigue syndrome: a narrative review[J]. Ther Adv Infect Dis, 2021, 8: 20499361211009385.
    [53] Singh I, Joseph P, Heerdt PM, et al. Persistent exertional intolerance after COVID -19: insights from invasive cardiopulmonary exercise testing[J]. Chest, 2022, 161(1): 54-63.
    [54] Tran VT, Porcher R, Pane I, et al. Course of post COVID -19 disease symptoms over time in the ComPaRe long COVID prospective e-cohort[J]. Nat Commun, 2022, 13(1): 1812.
    [55] Thakur M, Datusalia AK, Kumar A. Use of steroids in COVID -19 patients: a Meta-analysis[J]. Eur J Pharmacol, 2022, 914: 174579.
    [56] Kim JS, Lee JY, Yang JW, et al. Immunopathogenesis and treatment of cytokine storm in COVID -19[J]. Theranostics, 2021, 11(1): 316-329.
    [57] Pourahmad R, Moazzami B, Rezaei N. Efficacy of plasmaphe-resis and immunoglobulin replacement therapy (IVIG) on patients with COVID -19[J]. SN Compr Clin Med, 2020, 2(9): 1407-1411.
    [58] Andrade A, Dominski FH. Infographic. Effects of exercise in patients with fibromyalgia: an umbrella review[J]. Br J Sports Med, 2021, 55(5): 279-280.
    [59] Goldsmith RL, Bloomfield DM, Rosenwinkel ET. Exercise and autonomic function[J]. Coron Artery Dis, 2000, 11(2): 129-135.
    [60] Campbell H, Hotchkiss R, Bradshaw N, et al. Integrated care pathways[J]. BMJ, 1998, 316(7125): 133-137.
    网友评论
    网友评论
    分享到微博
    发 布
引用本文

张允旭,鞠萍,刘琪,等.新型冠状病毒感染后综合征的研究进展[J]. 中国感染控制杂志,2023,(9):1114-1120. DOI:10.12138/j. issn.1671-9638.20234314.
Yun-xu ZHANG, Ping JU, Qi LIU, et al. Research progress in post-COVID -19 syndrome[J]. Chin J Infect Control, 2023,(9):1114-1120. DOI:10.12138/j. issn.1671-9638.20234314.

复制
分享
文章指标
  • 摘要阅读次数:190
  • 下载次数: 531
  • HTML阅读次数: 997
  • 引用次数: 0
历史
  • 收稿日期:2023-04-06
  • 在线发布日期: 2024-04-28

中国感染控制杂志 ® 2025 版权所有 技术支持：北京勤云科技发展有限公司 湘ICP备17021739号-2